Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
Date | Price Target | Rating | Analyst |
---|---|---|---|
4/24/2025 | $85.00 | Equal Weight → Overweight | Fox Advisors |
9/4/2024 | $80.00 → $71.00 | Buy → Neutral | BofA Securities |
7/23/2024 | $65.00 | Hold | Vertical Research |
5/20/2024 | $150.00 | Buy | Seaport Research Partners |
4/9/2024 | $125.00 | Hold | Jefferies |
1/5/2024 | $117.00 | Buy | Citigroup |
10/5/2023 | $93.00 | Outperform | Exane BNP Paribas |
5/19/2023 | $91.00 → $77.00 | Outperform → Neutral | Credit Suisse |
The sale, marking a significant realization for the Fund IV continuation fund, represents the 11th announced or completed exit for Audax Private Equity since August 2024. Audax Private Equity ("Audax"), a capital partner for middle and lower middle market companies, announced today it has agreed to the sale of Trexon ("The Company"), a designer and manufacturer of custom interconnect solutions for mission critical applications. The sale to Amphenol Corporation (NYSE:APH) is subject to customary closing conditions and expected to close in the fourth quarter of 2025. Headquartered in Boston, MA, with 1,100 employees globally, Trexon delivers custom-engineered interconnect solutions, inclu
Amphenol Corporation (NYSE:APH) today announced a definitive agreement to acquire Trexon for approximately $1 billion in cash, subject to customary post-closing adjustments. Trexon is a leading provider of high-reliability interconnect and cable assemblies primarily for the defense market. Headquartered in Boston, Massachusetts and with facilities in the U.S. and the U.K., Trexon is expected to have 2025 sales and EBITDA margins of approximately $290 million and 26%, respectively. "We are extremely pleased to announce this agreement to add Trexon to the Amphenol family," said Amphenol President and Chief Executive Officer, R. Adam Norwitt. "Trexon's unique portfolio of high-reliability ca
Second Quarter Highlights Net sales of $1.39 billion GAAP income from continuing operations of $29.4 million Non-GAAP adjusted EBITDA of $337.8 million (1) Cash flow generated by operations of $77.1 million and free cash flow of $64.5 million (1) (2) (1) See "Non-GAAP Financial Measures" and "Reconciliation of GAAP Measures to Non-GAAP Adjusted Measures" below. (2) The cash flows related to discontinued operations have not been segregated. Accordingly, this cash flow information includes the results of continuing and discontinued operations. CommScope Holding Company, Inc. (NASDAQ:COMM), a global leader in network connectivity solutions, today reported results for the quart
4 - AMPHENOL CORP /DE/ (0000820313) (Issuer)
144 - AMPHENOL CORP /DE/ (0000820313) (Subject)
8-K - AMPHENOL CORP /DE/ (0000820313) (Filer)
10-Q - AMPHENOL CORP /DE/ (0000820313) (Filer)
4 - AMPHENOL CORP /DE/ (0000820313) (Issuer)
4 - AMPHENOL CORP /DE/ (0000820313) (Issuer)
4 - AMPHENOL CORP /DE/ (0000820313) (Issuer)
Fox Advisors upgraded Amphenol from Equal Weight to Overweight and set a new price target of $85.00
BofA Securities downgraded Amphenol from Buy to Neutral and set a new price target of $71.00 from $80.00 previously
Vertical Research initiated coverage of Amphenol with a rating of Hold and set a new price target of $65.00
TAMPA, Fla. and CORAL SPRINGS, Fla., Feb. 18, 2025 /PRNewswire/ -- HealthEdge Investment Partners, LLC ("HealthEdge"), a lower middle market private equity fund focused on healthcare, announced today that it has completed the sale of LifeSync ("LifeSync" or the "Company"), a developer, manufacturer, and marketer of disposable and reusable patient monitoring devices and connections sold to hospitals and other high acuity settings. LifeSync was acquired by Amphenol (NYSE:APH), one of the world's largest providers of connectors, interconnect systems, antennas, sensors and specialty cable. "When we first invested in LifeSync, our objective was to grow revenues and scale an entrepreneurial busin
Second Quarter Highlights Net sales of $1.39 billion GAAP income from continuing operations of $29.4 million Non-GAAP adjusted EBITDA of $337.8 million (1) Cash flow generated by operations of $77.1 million and free cash flow of $64.5 million (1) (2) (1) See "Non-GAAP Financial Measures" and "Reconciliation of GAAP Measures to Non-GAAP Adjusted Measures" below. (2) The cash flows related to discontinued operations have not been segregated. Accordingly, this cash flow information includes the results of continuing and discontinued operations. CommScope Holding Company, Inc. (NASDAQ:COMM), a global leader in network connectivity solutions, today reported results for the quart
Transaction highlights: To acquire CommScope's Connectivity and Cable Solutions business for $10.5 billion in cash Adds significant fiber optic interconnect capabilities for the IT datacom and communications networks markets as well as a diverse range of industrial interconnect products for the building infrastructure connectivity market Highly complementary to Amphenol's existing product offerings Anticipates CCS will generate sales and EBITDA margins of approximately $3.6 billion and 26% in 2025, respectively Expected to be accretive to Amphenol's Diluted EPS in first full year after closing Amphenol Corporation (NYSE:APH) today announced a definitive agreement to acquir
CommScope (NASDAQ:COMM), a global leader in network connectivity, announced today it has entered into a definitive agreement to sell its Connectivity and Cable Solutions (CCS) segment to Amphenol Corporation (NYSE:APH). CommScope (the "Company") is selling its CCS business to Amphenol for approximately USD $10.5 billion in cash, to be paid by Amphenol upon closing. The sale is expected to close within the first half of 2026, subject to customary closing conditions, including receipt of applicable regulatory approvals and the affirmative vote of the shareholders. The vote is required under Delaware law due to the nature and size of the transaction. The Company expects net proceeds after
SC 13G/A - AMPHENOL CORP /DE/ (0000820313) (Subject)
SC 13G/A - AMPHENOL CORP /DE/ (0000820313) (Subject)
SC 13G/A - AMPHENOL CORP /DE/ (0000820313) (Subject)